Avalon GloboCare Signs Agreement with Qi Diagnostics to Exclusively Distribute KetoAir Breathalyzer Device and AI-Enabled Software

Avalon GloboCare Corp, a developer of innovative cell-based technology, cellular therapy and precision diagnostics, announced that it has signed an agreement with Qi Diagnostics Limited (“Qi Diagnostics”), for exclusive distribution rights to market Qi Diagnostics’ KetoAir™ breathalyzer device and related accessories, including current and future models, in North America, South America, the U.K. and the European Union. KetoAir™ functions as companion diagnostic and monitoring device for ketogenic dietary management and will initially target the diabetes reversal and weight management markets.

AiThority Interview Insights: AiThority Interview with Oji Udezue, Chief Product Officer at Typeform

Qi Diagnostics is a medical device company with expertise in the development and manufacturing of proprietary Volatile Organic Compound (VOC) nanosensor-based in vitro diagnostic and screening devices. Qi Diagnostics has developed KetoAir™, a breathalyzer combined with an artificial intelligence (AI) nutritionist consultation for ketogenic health management that has been approved by the United States Food and Drug Administration.

Avalon and Qi-Diagnostics also intend to collaborate to co-develop a breathalyzer device for potential screening and early detection of lung cancer and will have joint ownership of any and all intellectual property arising from or generated in the co-development of a lung cancer breathalyzer product(s).

Read More about AiThority Interview: AiThority Interview with Kyle Wong, Chief Strategy Officer at Emplifi

“We are very excited to partner with Qi Diagnostics to exclusively distribute the KetoAir™ in North America, South America, the U.K. and the EU. Our initial go-to-market strategy will target diabetes reversal and obesity management. Increasing clinical evidence has demonstrated that nutritional ketosis is one of the most effective treatment options for sustainably reversing diabetes and weight management. A proper ketogenic diet has been clinically proven to reduce blood sugar, improve insulin sensitivity, and reduce inflammation,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “Being able to safely and consistently maintain nutritional ketosis has been shown to increase the chances of diabetes reversal. KetoAir™ is the first breathalyzer on the market that uses an artificial intelligence (AI) nutritionist bundled with the nanosensor-based breathalyzer for ketogenic health management. It can detect and quantify acetone levels in the breath and monitor the ketosis state, while also providing 24/7 nutritional advice. We look forward to commercializing KetoAir™ and helping those individuals with diabetes and weight management needs.”

 Latest AiThority Interview Insights : AiThority Interview with Jon Zimmerman, Chief Executive Officer at Holon Solutions

 [To share your insights with us, please write to sghosh@martechseries.com]